☐ ▓▓▓ Generate Collection ▓▓▓ | Print |

L3: Entry 1 of 1   File: PGPB   Apr 20, 2006

PGPUB-DOCUMENT-NUMBER: 20060083738
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060083738 A1

TITLE: Treatment of cancer by the use of anti fas antibody

PUBLICATION-DATE: April 20, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Johnston; Patrick Gerard	Belfast		GB
Longley; Daniel	Lisburn		GB

US-CL-CURRENT: 424/143.1; 514/34, 514/44, 514/449, 514/492

CLAIMS:

1-8. (canceled)

9. A method of killing cancer cells comprising administering a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent.

10. A method of treating cancer comprising administration of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent to a mammal in need thereof.

11. The method according to claim 9 or claim 10 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer.

12. The method according to claim 9 or 10 wherein the binding member is an antibody or a fragment thereof.

13. The method according to claim 9 or 10 wherein the death receptor is FAS.

14. The method according to claim 9 or 10 wherein the binding member is the anti-FAS antibody CH11.

15. The method according to claim 9 or 10 wherein the binding member comprises at least one human constant region.

16. The method according to claim 9 or 10 wherein said active agent is doxorubicin, oxaliplatin, taxol, tomudex, 5-Fluorouracil, Irinotecan or Cisplatin.

17. The method according to claim 16 wherein said active agent is tomudex or 5-Fluorouracil.

18. A product comprising a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent as a combined Preparation for the simultaneous, separate or sequential use in the treatment of cancer.

19. A pharmaceutical composition for the treatment of cancer, wherein the composition comprises a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent and (c) a pharmaceutically acceptable excipient, diluent or carrier.

20. (canceled)

21. The product according to claim 18 wherein the binding member is an antibody or a fragment thereof.

22. The product according to claim 18 wherein the death receptor is FAS.

23. The product according to claim 18 wherein the binding member is the anti-FAS antibody CH11.

24. The product according to claim 21 wherein the binding member comprises at least one human constant region.

25. The product according to claim 18 wherein said active agent is doxorubicin, oxaliplatin, taxol, tomudex, 5-Fluorouracil, Irinotecan or Cisplatin.

26. The product according to claim 25 wherein said active agent is tomudex or 5-Fluorouracil.

27. The pharmaceutical composition according to claim 19 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer.

28. The pharmaceutical composition according to claim 19 wherein the binding member is an antibody or a fragment thereof.

29. The pharmaceutical composition according to claim 19 wherein the death receptor is FAS.

30. The pharmaceutical composition according to claim 19 wherein the binding member is the anti-FAS antibody CH11.

31. The pharmaceutical composition according to claim 28 wherein the binding member comprises at least one human constant region.

32. The pharmaceutical composition according to claim 19 wherein said active agent is doxorubicin, oxaliplatin, taxol, tomudex, 5-Fluorouracil, Irinotecan or Cisplatin.

33. The pharmaceutical composition according to claim 32 wherein said active agent is tomudex or 5-Fluorouracil.